Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359931 | PMC |
| http://dx.doi.org/10.1111/jocs.15630 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic.
ESC Heart Fail
December 2024
Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Aims: Patients with cardiomyopathies are a heterogeneous group of patients who experience high morbidity and mortality. Early cardiac assessment and intervention with access to genetic counselling in a multidisciplinary Cardiomyopathy Clinic may improve outcomes and prevent progression to advanced heart failure.
Methods And Results: Our prospective cohort study was conducted at a multidisciplinary Cardiomyopathy Clinic with 421 patients enrolled (42.
In Response to: Reconsider the Indication of Implantable Cardioverter Defibrillator in Patients With Cardiac Amyloidosis.
J Cardiovasc Electrophysiol
December 2024
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Advances in studying the pathological mechanisms and treatment strategies of transthyretin amyloidosis.
J Cardiovasc Pharmacol
December 2024
Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Transthyretin amyloidosis (ATTR) is characterized by the deposition of unstable transthyretin protein (TTR) in the heart or peripheral nerves. Therapeutic strategies for ATTR include inhibition of the secretion of abnormal TTR by the liver, reducing the concentration of aberrant TTR in the circulation, and eliminating amyloid deposits of TTR in tissues. This article delves into the pathogenesis of TTR secretion from the liver into the bloodstream, its deposition in tissues, and the subsequent development of ATTR.
View Article and Find Full Text PDFCase Report: Avoiding misdiagnosis in amyloidosis-navigating transthyretin genopositivity and monoclonal gammopathy in a patient with advanced heart failure and spinal stenosis.
Front Cardiovasc Med
December 2024
Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, United States.
Background: A 63-year-old Black woman presented with progressive exertional dyspnea and chronic lower back pain. The course and findings in her case are instructive.
Case Report: Family history was notable for cardiac deaths.
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan.
Int J Hematol
December 2024
Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Kawasaki 1, Mizuno-cho, Mizuno-ku, Nagoya, Aichi, 467-8601, Japan.
This post-marketing surveillance (PMS) assessed the safety and effectiveness of isatuximab plus pomalidomide and dexamethasone (Isa-Pd) for relapsed or refractory multiple myeloma (RRMM) in frail individuals during real-world use in Japan. Data from all individuals with RRMM treated with Isa-Pd in Japan between October 2020 and October 2021 were collected, with follow-up continued up to 12 months after starting Isa-Pd or until discontinuation. In the overall PMS population, 40 participants were classified as frail (33.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!